Triple Therapy with GS-7977 Successful Against Hepatitis C
May 7, 2012
GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks
Produced in collaboration with hivandhepatitis.com
Published: 30 April 2012
Adding GS-7977 to pegylated interferon and ribavirin for 12 weeks led to a sustained response rate of 90% for previously untreated chronic hepatitis C patients with difficult-to-treat genotype 1, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.
Last year’s approval of the first direct-acting antiviral agents has changed the face of hepatitis C treatment. The first such drugs still must be taken with pegylated interferon and ribavirin, but they increase cure rates and offer the potential for shorter treatment.
Continue reading this entire article:
Boceprevir and HIV Drug Can Interact Dangerously
Concurrent Hepatitis C and Chronic Obstructive Pulmonary Disease